Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2019 - 2030

Purchase Option

$ 4400
$ 4000
$ 6000

Amyotrophic lateral sclerosis is the most common degenerative disease of the motor neuron system, enables destroy nerve cells and causes disability. Amyotrophic lateral sclerosis is known as Lou Gehrings disease. Amyotrophic lateral sclerosis often begins with muscle twitching and weakness in a limb, or slurred speech. Afterwards, may affects the control of the muscles involved in movement, speaking, eating and breathing. There is no cure for the disease and eventually disease is fatal. The disease is inherited in 5% to 10% of cases and rest is unknown etiology. Researchers are studying several possible causes including gene mutation, chemical imbalance, and protein mishandling and disorganized immune response.Amyotrophic lateral sclerosis is difficult to diagnose, because it mimics various neurological disease symptoms. Generally ALS diagnosed using electromyogram, nerve conduction study, MRI, spinal tap and muscle biopsy. Blood and urine test are performed to sort out the other possible signs and symptoms. Two FDA approved drugs are available in the market, namely Riluzole and endaravone. Various therapies are available to reduce the symptoms of the disease.

 Key Developments:

Most of the pipeline drugs for treatment of amyotrophic lateral sclerosis pipeline are at preclinical stages. Companies with pipeline molecules mostly focused on neuroprotection, immunomodulation,andglutamate excitotoxicity blockers for the treatment of amyotrophic lateral sclerosis.

  • In November 2017, U.S. Food and Drug Administration has given clearance of the clinical investigation of Biohaven Pharmaceuticals sublingual lead, BHV-0223 for the treatment of amyotrophic lateral sclerosis.
  • In September 2017, U.S. Food and Drug Administration granted orphan drug designation to Revalesios investigational drug RNS60 to treat Amyotrophic Lateral Sclerosis (ALS).

 

 

 

 

Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Dynamics

Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment report studies the various therapeutics under clinical development for uterine fibroids treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the uterine fibroids pipeline drugsdevelopment. This report studies the dynamics of the Amyotrophic Lateral SclerosisPipeline Drugs i.e. drivers, challenges,andopportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on uterine fibroids pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.

Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Segmentation

By Route of Administration
  • Oral
  • Parenteral
  • Others
By Trial Phase
  • Pre-clinical phase
  • Phase-I
  • Phase II
  • Phase-III

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario

1. Executive Summary

2. Global Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market Introduction

2.1. Global Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market Taxonomy

2.2. Global Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market Definitions

2.2.1. Route of Administration

2.2.2. Trial Phase

3. Global Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market Dynamics

3.1. Drivers

3.2. Restraints

3.3. Opportunities/Unmet Needs of the Market

3.4. Trends

3.5. Global Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market Dynamic Factors - Impact Analysis

3.6. Global Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market Competition Landscape

3.7. Epidemiology

4. Global Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market Analysis,2019 - 2023 and Forecast, 2018 2024

4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

4.3. Market opportunity analysis

5. Global Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market, By Route of Administration, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

5.1. Oral

5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.1.3. Market Opportunity Analysis

5.2. Parenteral

5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.2.3. Market Opportunity Analysis

5.3. Others

5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.3.3. Market Opportunity Analysis

6. Global Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market Forecast, By Trial Phase,2019 - 2023 and Forecast, 2017 2024

6.1. Pre-clinical phase

6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.1.3. Market Opportunity Analysis

6.2. Phase-I

6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.2.3. Market Opportunity Analysis

6.3. Phase II

6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.3.3. Market Opportunity Analysis

6.4. Phase-III

6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.4.3. Market Opportunity Analysis

7. Global Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market Forecast, By Region, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

7.1. North America

7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.1.3. Market Opportunity Analysis

7.2. Europe

7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.2.3. Market Opportunity Analysis

7.3. Asia-Pacific

7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.3.3. Market Opportunity Analysis

7.4. Latin America

7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.4.3. Market Opportunity Analysis

7.5. Middle East and Africa

7.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.5.3. Market Opportunity Analysis

7.6. Global Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Route of Administration, By Trial Phase and Region, 2018 2024

8. North America Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment MarketAnalysis,2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

8.1. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)

8.1.1. Oral

8.1.2. Parenteral

8.1.3. Others

8.2. Trial Phase Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

8.2.1. Pre-clinical phase

8.2.2. Phase-I

8.2.3. Phase II

8.2.4. Phase-III

8.3. Country Analysis 2016 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

8.3.1. U.S.

8.3.2. Canada

8.4. North America Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Route of Administration, By Trial Phase and Country, 2018 2024

8.5. North America Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market Dynamics Trends

9. Europe Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

9.1. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)

9.1.1. Oral

9.1.2. Parenteral

9.1.3. Others

9.2. Trial Phase Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

9.2.1. Pre-clinical phase

9.2.2. Phase-I

9.2.3. Phase II

9.2.4. Phase-III

9.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

9.3.1. Germany

9.3.2. UK

9.3.3. France

9.3.4. Spain

9.3.5. Italy

9.3.6. Russia

9.3.7. Poland

9.3.8. Rest of Europe

9.4. Europe Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Route of Administration, By Trial Phase and Country,2018 2024

9.5. Europe Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market Dynamics Trends

10. Asia-Pacific Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

10.1. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)

10.1.1. Oral

10.1.2. Parenteral

10.1.3. Others

10.2. Trial Phase Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.2.1. Pre-clinical phase

10.2.2. Phase-I

10.2.3. Phase II

10.2.4. Phase-III

10.3. Country Analysis2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)       

10.3.1. Japan

10.3.2. China

10.3.3. India

10.3.4. ASEAN

10.3.5. Australia & New Zealand

10.3.6. Rest of Asia-Pacific

10.4. Asia-Pacific Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Route of Administration, By Trial Phase and Country,2018 2024

10.5. Asia-Pacific Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market Dynamics Trends

11. Latin America Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market Analysis, 2012 - 2012 - 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

11.1. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)

11.1.1. Oral

11.1.2. Parenteral

11.1.3. Others

11.2. Trial Phase Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.2.1. Pre-clinical phase

11.2.2. Phase-I

11.2.3. Phase II

11.2.4. Phase-III

11.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

11.3.1. Brazil

11.3.2. Mexico

11.3.3. Argentina

11.3.4. Venezuela

11.3.5. Rest of Latin America

11.4. Latin America Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Route of Administration, By Trial Phase and Country,2018 2024

11.5. Latin America Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market Dynamics Trends

12. Middle East and Africa Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

12.1. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)

12.1.1. Oral

12.1.2. Parenteral

12.1.3. Others

12.2. Trial Phase Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.2.1. Pre-clinical phase

12.2.2. Phase-I

12.2.3. Phase II

12.2.4. Phase-III

12.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

12.3.1. Gulf Cooperation Council (GCC) Countries

12.3.2. Israel

12.3.3. South Africa

12.3.4. Rest of MEA

12.4. MEA Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Route of Administration, By Trial Phase and Country,2018 2024

12.5. MEA Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market Dynamics Trends

13. Competition Landscape

13.1. Strategic Dashboard of Top Market Players

13.2. Company Profiles (Introduction, Financial Analysis, Route of Administration& Service Offerings, Key Developments, Strategies, and SWOT Analysis)

13.2.1. Mallinckrodt Pharmaceuticals

13.2.2. ASTELLAS PHARMA INC. (JAPAN)

13.2.3. REVALESIO CORPORATION (U.S.)

13.2.4. Amylyx Pharmaceutical Corp. (U.S.)

13.2.5. Mitsubishi Tanabe Pharma Corporation (Japan)

13.2.6. AB Science (France)

13.2.7. H. Boehringer Sohn AG &Co. KG (Germany)

14. Research Methodology

15. Key Assumptions and Acronyms

  • Mallinckrodt Pharmaceuticals
  • ASTELLAS PHARMA INC. (JAPAN)
  • REVALESIO CORPORATION (U.S.)
  • Amylyx Pharmaceutical Corp. (U.S.)
  • Mitsubishi Tanabe Pharma Corporation (Japan)
  • AB Science (France)
  • H. Boehringer Sohn AG &Co. KG (Germany)

Adjacent Markets

Single-cell Technologies Market
Live Cell Imaging Market
Infusion Pumps Market
Enteral Feeding Pumps Market
X-linked Hypophosphatemia (XLH) Market
Tumor-induced Osteomalacia (TIO) Drugs Market